What is HC Wainwright’s Estimate for Annexon Q1 Earnings?

Annexon, Inc. (NASDAQ:ANNX) – Research analysts at HC Wainwright issued their Q1 2025 earnings estimates for Annexon in a research note issued to investors on Tuesday, March 4th. HC Wainwright analyst A. Fein forecasts that the company will post earnings per share of ($0.33) for the quarter. HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for Annexon’s current full-year earnings is ($0.96) per share. HC Wainwright also issued estimates for Annexon’s FY2025 earnings at ($1.31) EPS, FY2026 earnings at ($1.37) EPS, FY2027 earnings at ($0.78) EPS and FY2028 earnings at ($0.28) EPS.

ANNX has been the topic of a number of other reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a research note on Friday, November 15th. Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 target price on shares of Annexon in a report on Tuesday, March 4th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $15.80.

Annexon Price Performance

NASDAQ:ANNX opened at $2.76 on Friday. Annexon has a 1 year low of $2.30 and a 1 year high of $8.40. The stock’s fifty day moving average price is $3.75 and its two-hundred day moving average price is $5.33. The company has a market cap of $294.20 million, a P/E ratio of -2.63 and a beta of 1.14.

Annexon (NASDAQ:ANNX) last released its quarterly earnings data on Monday, March 3rd. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.05).

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ANNX. TFG Asset Management GP Ltd grew its position in Annexon by 78.5% during the fourth quarter. TFG Asset Management GP Ltd now owns 1,400,000 shares of the company’s stock worth $7,182,000 after buying an additional 615,645 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of Annexon during the fourth quarter worth about $252,000. Shay Capital LLC purchased a new position in shares of Annexon during the fourth quarter worth about $159,000. Sphera Funds Management LTD. bought a new position in shares of Annexon in the fourth quarter worth approximately $6,377,000. Finally, Rafferty Asset Management LLC raised its stake in Annexon by 23.5% in the fourth quarter. Rafferty Asset Management LLC now owns 218,369 shares of the company’s stock valued at $1,120,000 after purchasing an additional 41,544 shares in the last quarter.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.